On December 17th, CorningJereh Pharmaceutical (09966) announced that its Investigational New Drug (IND) application for its independently developed programmed death-ligand 1 (PD-L1)/vascular endothelial growth factor receptor 2 (VEGFR2) bispecific antibody-drug conjugate (ADC) JSKN027 has been formally accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).

　　The company plans to conduct a Phase I clinical study of JSKN027 for the treatment of advanced malignant solid tumors, aiming to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity in this patient population, and to determine the maximum tolerated dose and/or recommended Phase II dose.

　　JSKN027 is the world's first PD-L1/VEGFR2 bispecific antibody ADC to enter clinical trials. Preclinical data show that JSKN027 exhibits significant tumor-suppressive activity in both in vitro and in vivo models, and GLP toxicology studies demonstrate good tolerability at the highest dose. Based on its multiple mechanisms of action, including cytotoxicity, anti-angiogenesis, and immunomodulation, JSKN027 holds promise for providing new treatment options for various solid tumors.

https://finance.eastmoney.com/a/202512173594365741.html